Enterprise Value

-23.02M

Cash

245.9M

Avg Qtr Burn

-36.64M

Short % of Float

6.72%

Insider Ownership

5.67%

Institutional Own.

82.93%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tarcocimab (KSI-301) (anti-VEGF) Details
Non-proliferative diabetic retinopathy

Phase 3

Data readout

KSI-501 (anti-VEGF & IL-6) Details
Eye disease , Wet age-related macular degeneration

Phase 3

Initiation

KSI-101 Details
Eye disease

Phase 1b

Initiation

KSI-501 (anti-VEGF & IL-6) Details
Diabetic macular edema, Eye disease

Phase 1

Update

Tarcocimab (KSI-301) Details
Wet age-related macular degeneration

Failed

Discontinued

Failed

Discontinued

Tarcocimab (KSI-301) Details
Retinal vein occlusion

Failed

Discontinued